Article
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
The oncologist - 1 Jan 2012
Oizumi Satoshi, Kobayashi Kunihiko, Inoue Akira, Maemondo Makoto, Sugawara Shunichi, Yoshizawa Hirohisa, Isobe Hiroshi, Harada Masao, Kinoshita Ichiro, Okinaga Shoji, Kato Terufumi, Harada Toshiyuki, Gemma Akihiko, Saijo Yasuo, Yokomizo Yuki, Morita Satoshi, Hagiwara Koichi, Nukiwa Toshihiro
Abstract excerpt
BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. This report describes the quality of life (QoL) analysis of that study. METHODS: Chemotherapy-naïve...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.